Pfizer (PFE) Initiates Phase 1 Study of Novel Oral Antiviral Therapeutic Agent Against SARS-CoV-2

Go back to Pfizer (PFE) Initiates Phase 1 Study of Novel Oral Antiviral Therapeutic Agent Against SARS-CoV-2
Pfizer Inc. (NYSE: PFE) Delayed: 39.19 -0.39 (0.99%)
Previous Close $39.58    52 Week High $37.39 
Open $38.48    52 Week Low $28.25 
Day High $39.23    P/E 23.75 
Day Low $37.96    EPS $1.65 
Volume 55,033,753